Q3 EPS Estimates for Eton Pharmaceuticals Cut by B. Riley

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at B. Riley lowered their Q3 2025 earnings estimates for Eton Pharmaceuticals in a report issued on Thursday, May 15th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of $0.10 for the quarter, down from their previous estimate of $0.11. B. Riley currently has a “Buy” rating and a $26.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ FY2027 earnings at $1.91 EPS, FY2028 earnings at $2.29 EPS and FY2029 earnings at $2.52 EPS.

ETON has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, May 14th.

Eton Pharmaceuticals Price Performance

Shares of Eton Pharmaceuticals stock opened at $18.93 on Monday. The firm has a market cap of $507.66 million, a P/E ratio of -86.05 and a beta of 1.22. The firm has a 50 day simple moving average of $14.82 and a 200 day simple moving average of $13.96. Eton Pharmaceuticals has a fifty-two week low of $3.18 and a fifty-two week high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). The company had revenue of $17.28 million during the quarter, compared to analyst estimates of $14.33 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. AlphaQuest LLC bought a new position in Eton Pharmaceuticals in the first quarter valued at approximately $53,000. Tower Research Capital LLC TRC bought a new position in Eton Pharmaceuticals in the fourth quarter valued at approximately $86,000. Quantbot Technologies LP bought a new position in Eton Pharmaceuticals in the first quarter valued at approximately $101,000. Jefferies Financial Group Inc. bought a new position in Eton Pharmaceuticals in the fourth quarter valued at approximately $133,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its stake in Eton Pharmaceuticals by 18.3% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock valued at $141,000 after acquiring an additional 1,634 shares during the last quarter. 27.86% of the stock is owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.